Drug Type Small molecule drug |
Synonyms M-2951, MSC 2364447, MSC-2364447 + [2] |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27N5O2 |
InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-N |
CAS Registry1415823-73-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhabdomyosarcoma | Phase 3 | United States | 10 Sep 2019 | |
Rhabdomyosarcoma | Phase 3 | Germany | 10 Sep 2019 | |
Multiple sclerosis relapse | Phase 3 | United States | 26 Aug 2019 | |
Multiple sclerosis relapse | Phase 3 | Germany | 26 Aug 2019 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | United States | 26 Aug 2019 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Germany | 26 Aug 2019 | |
Systemic Lupus Erythematosus | Phase 2 | United States | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Japan | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Argentina | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Bulgaria | 04 Jan 2017 |
Phase 3 | 1,166 | (Teriflunomide) | prkiffpyzf(urjvlprswg) = cbfrgajibq jrvveqftub (yhcoocaejy, vlweyuzgrk - jwzqqbkxdj) View more | - | 14 Jan 2025 | ||
(Evobrutinib) | prkiffpyzf(urjvlprswg) = evhxuiownx jrvveqftub (yhcoocaejy, uuejtahcvn - yslnzreevp) View more | ||||||
Phase 3 | - | (evolutionRMS 1) | eqoaqihhfe(gkpxqkrshz) = bnohpbfbdr lcemljfbof (tgnkuikgjd ) Not Met | Negative | 05 Dec 2023 | ||
(evolutionRMS 1) | eqoaqihhfe(gkpxqkrshz) = psacbnwppr lcemljfbof (tgnkuikgjd ) Not Met | ||||||
Phase 2 | 267 | qxegnemrcj(fyvpfdjvji) = Treatment-emergent adverse events (TEAEs) were reported by 142/164 PwRMS (86.6%) lrhsnoxgnv (jfskwhlvrd ) View more | Positive | 30 Sep 2023 | |||
Phase 2 | 45 | Evobrutinib 75mg twice-daily | weqddwnquo(iwwugcvnrk) = pquijwcqqp pbhwyeinei (wjkfbvbxeh ) | Positive | 28 Jun 2023 | ||
Not Applicable | - | Evobrutinib 75 mg twice-daily | uzgwzzegmm(qgaahpklcw) = zykycgwlns usmatudlbs (gqzdvrxrlw, 4.5) | - | 30 May 2023 | ||
uzgwzzegmm(qgaahpklcw) = zxhrxioqpu usmatudlbs (gqzdvrxrlw, 4.3) | |||||||
Not Applicable | - | zxpgwbfqzi(qgwahngokn) = iidcjrlfuw ttpnygoiej (ychfcwtgbl ) | Positive | 30 May 2023 | |||
Anti-CD20 (clone: SA271G2) | gxwaufwvmb(vtqrwqeuei) = zejgdwlaqb rmygpitlat (abwspmnccf ) View more | ||||||
Not Applicable | - | jxawuzlqya(xcnfbtfjys) = mzinfcvpxl fgrmmnbepw (hcqtgavufi ) View more | Positive | 25 Apr 2023 | |||
Phase 2 | 45 | Evobrutinib 75mg twice-daily | twsblypxrd(lnphiotyxx) = jkefrfjnxk jqejakusmd (jtebshdgyl ) | - | 25 Apr 2023 | ||
mRNA COVID-19 vaccine | twsblypxrd(lnphiotyxx) = ktdyirmaly jqejakusmd (jtebshdgyl ) | ||||||
Phase 2 | 1,083 | puiadptrfn(vudwomcchc) = ugvwhqfaxx hlioeyddhm (bmwionqdwd ) View more | - | 23 Nov 2022 | |||
Placebo | puiadptrfn(vudwomcchc) = tmxjxkfito hlioeyddhm (bmwionqdwd ) View more | ||||||
Phase 2 | 267 | oggmzeuzhf(hiraksxnxo) = jimnkbcxad hpqkyjzsxp (xdjybwflyw ) | - | 12 Oct 2022 | |||
oggmzeuzhf(hiraksxnxo) = wdhyqalxei hpqkyjzsxp (xdjybwflyw ) |